Polo-like kinase 2 regulates selective autophagic synuclein clearance and suppresses its toxicity in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 41, 2013, Pages

  Oueslati, Abid ^a   Schneider, Bernard L ^b   Aebischer, Patrick ^b   Lashuel, Hilal A ^a  

^a Laboratory of Molecular and Chemical Biology of Neurodegeneration   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

Adeno associated virus; Animal model; Serum inducible kinase

Indexed keywords

ALPHA SYNUCLEIN; POLO LIKE KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOTOR DYSFUNCTION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REGULATORY MECHANISM; UPREGULATION;

ADENO-ASSOCIATED VIRUS; ANIMAL MODEL; SERUM INDUCIBLE KINASE;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; RATS;

EID: 84885363886     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1309991110     Document Type: Article

References (59)

1. Lang AE, Lozano AM (1998) Parkinson's disease: First of two parts. N Engl J Med 339 (15):1044-1053.
2. Lang AE, Lozano AM (1998) Parkinson's disease: Second of two parts. N Engl J Med 339(16):1130-1143.
3. Obeso JA, et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16(6): 653-661.
4. SpillantiniMG, Crowther RA, Jakes R, Hasegawa M, Goedert M(1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95(11):6469-6473.
5. Lee VM, Trojanowski JQ (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron 52(1):33-38.
6. Muntané G, Ferrer I, Martinez-Vicente M (2012) α-Synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106-119.
7. Hasegawa M, et al. (2002) Phosphorylated alpha-synuclein is ubiquitinated in alphasynucleinopathy lesions. J Biol Chem 277(50):49071-49076.
8. Fujiwara H, et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160-164.
9. Anderson JP, et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281(40):29739-29752.
10. Kahle PJ, et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3(6):583-588.
11. Neumann M, et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110(10):1429-1439.
12. Takahashi M, et al. (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett 336(3):155-158.
13. Mbefo MK, et al. (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285(4):2807-2822.
14. Inglis KJ, et al. (2009) Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem 284(5):2598-2602.
15. Salvi M, et al. (2012) Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants. Biochem Biophys Res Commun 418(1):156-160.
16. Xie S, Xie B, Lee MY, Dai W (2005) Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 24(2):277-286.
17. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I (2005) Polo-like kinases (Plks) and cancer. Oncogene 24(2):287-291.
18. Eckerdt F, Yuan J, Strebhardt K (2005) Polo-like kinases and oncogenesis. Oncogene 24(2):267-276.
19. Seeburg DP, Pak D, ShengM (2005) Polo-like kinases in the nervous system. Oncogene 24(2):292-298.
20. McCormack AL, Mak SK, Di Monte DA (2012) Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis 3:e315.
21. Pronin AN, Morris AJ, Surguchov A, Benovic JL (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275(34):26515-26522.
22. Sakamoto M, et al. (2009) Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells. Biochem Biophys Res Commun 384(3):378-382.
23. Evers DM, et al. (2010) Plk2 attachment to NSF induces homeostatic removal of GluA2 during chronic overexcitation. Nat Neurosci 13(10):1199-1207.
24. Pak DT, Sheng M (2003) Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science 302(5649):1368-1373.
25. Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci 32(5): 1536-1544.
26. Azeredo da Silveira S, et al. (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet 18(5):872-887.
27. Gaugler MN, et al. (2012) Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol 123(5):653-669.
28. McFarland NR, et al. (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 68(5):515-524.
29. Zhou J, et al. (2011) Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol 121(6):695-704.
30. Waxman EA,Giasson BI (2011) Characterization of kinases involved in the phosphorylation of aggregated α-synuclein. J Neurosci Res 89(2):231-247.
31. Wang S, et al. (2012) α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc Natl Acad Sci USA 109(40):16119-16124.
32. Paleologou KE, et al. (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283(24):16895-16905.
33. Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y (2007) Pharmacological and functional comparison of the polo-like kinase family: Insight into inhibitor and substrate specificity. Biochemistry 46(33):9551-9563.
34. Machiya Y, et al. (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 285(52): 40732-40744.
35. Chau KY, Ching HL, Schapira AH, Cooper JM (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: Relevance to Parkinson's disease pathogenesis. J Neurochem 110(3):1005-1013.
36. CizmeciogluO, et al. (2012) Plk2 regulates centriole duplication through phosphorylationmediated degradation of Fbxw7 (human Cdc4). J Cell Sci 125(Pt 4):981-992.
37. Seeburg DP, Feliu-Mojer M, Gaiottino J, Pak DT, Sheng M (2008) Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron 58(4):571-583.
38. Seeburg DP, Sheng M (2008) Activity-induced Polo-like kinase 2 is required for homeostatic plasticity of hippocampal neurons during epileptiform activity. J Neurosci 28(26):6583-6591.
39. Lee KJ, et al. (2011) Requirement for Plk2 in orchestrated ras and rap signaling, homeostatic structural plasticity, and memory. Neuron 69(5):957-973.
40. Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain. Nat Rev Neurosci 7(1):30-40.
41. Picconi B, Piccoli G, Calabresi P (2012) Synaptic dysfunction in Parkinson's disease. Adv Exp Med Biol 970:553-572.
42. Gitler AD, et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41(3): 308-315.
43. Visanji NP, et al. (2011) Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. J Biol Chem 286(41):35863-35873.
44. Sancenon V, et al. (2012) Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. Hum Mol Genet 21(11):2432-2449.
45. Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8(5): 657-663.
46. Sato H, et al. (2011) Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31(46): 16884-16894.
47. Nemani VM, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66-79.
48. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38-48.
49. Burré J, et al. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329(5999):1663-1667.
50. McFarland MA, Ellis CE, Markey SP, Nussbaum RL (2008) Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics 7(11):2123-2137.
51. Ebrahimi-Fakhari D, Wahlster L, McLean PJ (2012) Protein degradation pathways in Parkinson's disease: Curse or blessing. Acta Neuropathol 124(2):153-172.
52. Paleologou KE, et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30(9):3184-3198.
53. Volpicelli-Daley LA, et al. (2011) Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57-71.
54. Schell H, Hasegawa T, Neumann M, Kahle PJ (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 160 (4):796-804.
55. Krause A, Hoffmann I (2010) Polo-like kinase 2-dependent phosphorylation of NPM/ B23 on serine 4 triggers centriole duplication. PLoS ONE 5(3):e9849.
56. Warnke S, et al. (2004) Polo-like kinase-2 is required for centriole duplication in mammalian cells. Curr Biol 14(13):1200-1207.
57. Cizmecioglu O, Warnke S, Arnold M, Duensing S, Hoffmann I (2008) Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle 7(22):3548-3555.
58. Dusonchet J, Bensadoun JC, Schneider BL, Aebischer P (2009) Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol Dis 35(1):32-41.
59. West MJ (1999) Stereological methods for estimating the total number of neurons and synapses: Issues of precision and bias. Trends Neurosci 22(2):51-61.